Aware Super Pty Ltd increased its position in Bristol Myers Squibb (NYSE:BMY) by purchasing 328,003 shares valued at approximately $19.9 million during the first quarter. This move joins a list of other institutional investors, including Swiss RE and various wealth management firms, who have recently established or expanded stakes in the biopharmaceutical company, with hedge funds collectively owning 76.41% of the outstanding stock.
Bristol Myers Squibb's stock opened at $60.47 on Friday, trading against a market capitalization of $123.48 billion and a price-to-earnings ratio of 16.99. The company recently declared a quarterly dividend of $0.63 per share, payable on August 3rd to shareholders of record as of July 2nd, resulting in an annualized yield of 4.2% with a payout ratio of 70.79%. Technical indicators show the stock trading above its fifty-day moving average but below its 200-day average.
Analyst sentiment remains mixed regarding the company's future prospects. While UBS Group maintained a 'buy' rating and Bank of America lowered its price objective to $66, Cantor Fitzgerald issued a 'neutral' rating with a $54 target. The consensus among eight investment analysts is currently a 'Hold' with an average price target of $61.25. Bristol Myers Squibb continues to focus on its core portfolio in oncology and immune-mediated conditions through small molecules and biologics.
📈 Aware Super bought 328,003 shares worth $19.9 million in Q1.
🏦 Institutional ownership is high at 76.41% with new stakes added.
💰 Quarterly dividend of $0.63 per share payable August 3rd.
📊 Market cap is $123.48 billion with a P/E ratio of 16.99.
🎯 Analyst consensus is 'Hold' with an average price target of $61.25.
📈 Aware Super Pty Ltd acquired a new position of 328,003 shares valued at approximately $19.9 million in the first quarter.
🏦 Institutional ownership remains high at 76.41%, with other firms like Swiss RE and Darwin Wealth Management adding new stakes.
💰 The company declared a quarterly dividend of $0.63 per share, payable on August 3rd to investors of record by July 2nd.
📊 Bristol Myers Squibb trades at a market cap of $123.48 billion with a P/E ratio of 16.99 and a beta of 0.23.
📉 The stock opened at $60.47, trading above its fifty-day moving average of $56.93 but below the 200-day average of $57.76.
🎯 Analyst consensus is currently a 'Hold' with an average price target of $61.25 based on data from MarketBeat.com.
📉 Bank of America reduced its price objective to $66 while maintaining a 'buy' rating in a recent research note.
⚖️ Cantor Fitzgerald reissued a 'neutral' rating with a lower price objective of $54.00 for the biopharmaceutical stock.
🔬 The company focuses on discovering and delivering medicines for serious diseases, specifically in oncology and immune-mediated conditions.
💸 The dividend payout ratio stands at 70.79%, representing an annualized yield of 4.2%.
Bullish Signals
Institutional confidence shown by $19.9 million new position.
Risk Factors
Neutral $54 target below current ~$60 price.
BofA cut target from $67 to $66.
Stock trades below 200-day moving average of $57.76.
Weiss Ratings restated hold (c+) with caution.
Bullish Signals
Aware Super Pty Ltd established a significant new position valued at $19.9 million, indicating institutional confidence in the company's long-term prospects.
The company maintains a strong dividend profile with a 4.2% annualized yield and a payout ratio of 70.79%, providing steady income to shareholders.
UBS Group restated a 'buy' rating on the stock, signaling continued analyst support for Bristol Myers Squibb's strategic direction.
The firm holds a robust balance sheet with a quick ratio of 1.28 and a current ratio of 1.42, ensuring liquidity for ongoing operations.
Risk Factors
Cantor Fitzgerald issued a 'neutral' rating with a price objective of $54.00, which is significantly below the current trading price of approximately $60.
Bank of America reduced its price target from $67.00 to $66.00, suggesting potential downside pressure or a more conservative valuation outlook.
The stock trades below its 200-day moving average of $57.76, indicating some short-term weakness relative to longer-term trends.
Weiss Ratings restated a 'hold (c+)' rating, reflecting cautious sentiment among analysts regarding the company's immediate performance.
Bristol-Myers Squibb (NYSE:BMY) is highlighted as a top-tier cash-rich dividend stock, ranking second on a list of eight such companies. The article notes that corporate cash reserves have reached an all-time high of $4.11 trillion in Q1 2024, driven by strong economic conditions and elevated interest rates, with many corporations earning significant interest income on these holdings.
BMY reported nearly $12 billion in revenue for the third quarter of 2024, an 8.5% increase year-over-year, fueled by growth in its oncology portfolio. The company holds approximately $8 billion in cash and cash equivalents as of the end of the quarter, maintaining a robust balance sheet that supports its status as a solid dividend payer with payouts increased for 18 consecutive years.
Financial metrics show BMY generated $15 billion in operating cash flow and $17.52 billion in levered free cash flow over the trailing twelve months. The stock currently offers a 4.44% dividend yield with a quarterly payout of $0.60 per share. Hedge fund interest has grown, with stakes held by 70 funds totaling over $3.3 billion as of Q3 2024.
Despite its strong fundamentals and cash position, the article suggests that BMY may not offer the highest potential returns compared to AI stocks trading at low valuations. The stock has risen nearly 6% since the start of 2024 following FDA approval for its schizophrenia treatment Cobenfy, though the author maintains a preference for higher-growth sectors.
📈 BMY ranks second among eight recommended cash-rich dividend stocks.
💰 Q3 2024 revenue hit $12 billion, an 8.5% year-over-year increase.
🏦 The company holds approximately $8 billion in cash and equivalents.
💵 Stock offers a 4.44% yield with a $0.60 quarterly payout.
🔍 Hedge fund stakes rose to over $3.3 billion across 70 funds.
📈 Bristol-Myers Squibb (BMY) ranks second on a list of eight cash-rich dividend stocks recommended for investment.
💰 The company reported $12 billion in Q3 2024 revenue, representing an 8.5% increase from the prior year.
🏦 BMY holds approximately $8 billion in cash and cash equivalents as of the end of the third quarter.
💵 The stock offers a 4.44% dividend yield with a quarterly payout of $0.60 per share.
📊 Over the trailing twelve months, operating cash flow reached $15 billion and levered free cash flow hit $17.52 billion.
🔍 Hedge fund ownership increased to 70 funds in Q3 2024, with collective stakes valued at over $3.3 billion.
💊 The FDA approved Cobenfy for schizophrenia treatment in September, contributing to a nearly 6% stock surge since the start of 2024.
📉 Oncology portfolio expansion and efficient operational management drove the strong third-quarter financial performance.
🧠 Analysts note that while BMY is solid, AI stocks may offer higher returns within shorter time frames.
📅 The article was published on December 18, 2024, analyzing data through mid-December 2023 and Q3 2024.
Bullish Signals
Revenue up 8.5% to $12B in Q3 2024.
$8B cash position as of late Q3 2024.
Dividend increased for 18 consecutive years.
Levered free cash flow hit $17.52 billion.
Hedge fund stakes grew to 70 funds totaling $3.3B.
Risk Factors
AI stocks may outperform BMY faster, limiting relative upside.
BMY ranks second for cash-rich dividends, implying better alternatives exist.
Bullish Signals
BMY reported an 8.5% year-over-year revenue increase to nearly $12 billion in the third quarter of 2024.
The company maintains a strong cash position with approximately $8 billion in cash and cash equivalents as of late Q3 2024.
BMY has increased its dividend payouts for 18 consecutive years, demonstrating a long history of shareholder returns.
Levered free cash flow reached $17.52 billion over the trailing twelve months, providing ample flexibility for future dividends or acquisitions.
Hedge fund sentiment is positive, with tracked stakes growing from 61 to 70 funds in Q3 2024, totaling over $3.3 billion.
The stock has gained nearly 6% since the start of 2024 following FDA approval for its schizophrenia drug Cobenfy.
Risk Factors
The article suggests that AI stocks may offer higher returns than BMY within a shorter time frame, potentially limiting relative upside.
BMY ranks second on the author's list of cash-rich dividend stocks, implying other companies in the same category might be viewed as superior.
Hudson Edge Investment Partners Inc. reduced its stake in Bristol Myers Squibb (NYSE:BMY) by 17.7% during the first quarter, selling 29,888 shares to hold a remaining position of 138,879 shares valued at $8.42 million. This reduction brings BMY to 1.2% of Hudson Edge's total holdings, marking it as the firm's 12th largest position according to recent SEC 13F filings.
Conversely, several major institutional investors increased their stakes in Bristol Myers Squibb during the fourth quarter. Vanguard Group boosted its position by 1.4% to own nearly 199 million shares worth over $10.7 billion, while State Street Corp and Geode Capital Management also added significant holdings. Norges Bank initiated a new stake valued at approximately $1.95 billion, and AQR Capital Management surged its position by 172.6%.
The article details Bristol Myers Squibb's current financial metrics, noting a market capitalization of $118.54 billion and a dividend yield of 4.3%. The company recently declared a quarterly dividend of $0.63 per share payable on August 3rd for shareholders of record on July 2nd. Analyst consensus remains mixed with a 'Hold' rating and a price target of $61.31, though recent upgrades from Wall Street Zen and UBS suggest continued institutional interest.
Bristol Myers Squibb operates as a global biopharmaceutical company headquartered in Princeton, New Jersey, focusing on oncology, hematology, immunology, and cardiovascular disease. The firm's portfolio emphasizes cancer and immune-mediated conditions through both small molecules and biologics. Institutional ownership stands at 76.41%, reflecting broad market confidence despite the recent reduction by Hudson Edge Investment Partners.
📉 Hudson Edge sold 29,888 shares, retaining $8.42 million stake.
📈 Vanguard owns 198.7M shares valued at $10.7 billion.
🇳🇴 Norges Bank started new $1.95 billion position in Q4.
💰 BMY pays $0.63 dividend with 4.3% yield ex-July 2nd.
📊 Market cap is $118.54B with PE ratio of 16.31.
📉 Hudson Edge Investment Partners Inc. reduced its Bristol Myers Squibb stake by 17.7% in Q1, selling 29,888 shares to retain a position worth $8.42 million.
📈 Vanguard Group increased its BMY holdings by 1.4% in Q4, now owning 198,727,768 shares valued at approximately $10.7 billion.
📈 State Street Corp and Geode Capital Management also boosted their positions by 1.4% and 13.1% respectively during the fourth quarter.
🇳🇴 Norges Bank initiated a new stake in Bristol Myers Squibb valued at roughly $1.95 billion in Q4.
📈 AQR Capital Management significantly increased its position by 172.6%, acquiring an additional 16.3 million shares worth $1.39 billion.
💰 BMY declared a quarterly dividend of $0.63 per share with an ex-dividend date of July 2nd and a yield of 4.3%.
📊 The company trades at a market cap of $118.54 billion with a PE ratio of 16.31 and a beta of 0.23.
📈 Wall Street Zen upgraded BMY to a 'strong-buy' rating, while UBS reissued a 'buy' rating on the stock.
🎯 Analyst consensus remains 'Hold' with a price target of $61.31 based on ratings from eight buy, ten hold, and one sell analysts.
💊 Bristol Myers Squibb focuses its R&D and commercialization efforts on oncology, hematology, immunology, and cardiovascular diseases.
Bullish Signals
Major institutions increased stakes in Q4.
Strong 4.3% dividend yield with 70.79% payout ratio.
Wall Street Zen upgraded to strong-buy.
Guggenheim price target set at $72.00.
Institutional ownership stands at 76.41%.
Risk Factors
Major investor reduced stake by 17.7% in Q1.
Analyst price target of $61.31 is below current range.
One analyst assigned a 'Sell' rating.
Bullish Signals
Major institutional investors including Vanguard, State Street, Geode Capital, Norges Bank, and AQR Capital Management all increased their stakes in the fourth quarter.
The company maintains a strong dividend yield of 4.3% with a payout ratio of 70.79%, providing consistent income to shareholders.
Wall Street Zen upgraded the stock from 'buy' to 'strong-buy', and UBS reissued a 'buy' rating, indicating analyst confidence.
Guggenheim reiterated a 'buy' rating and set a price target of $72.00, which is above the current trading price.
Institutional ownership remains high at 76.41%, suggesting broad support from large asset managers.
Risk Factors
Hudson Edge Investment Partners Inc. reduced its stake by 17.7% in Q1, signaling a decrease in interest from this specific investor.
The consensus analyst rating is 'Hold' with a price target of $61.31, which is below the current stock price of approximately $58.05 to $62.89 range depending on recent movement.
One analyst has assigned a 'Sell' rating to the company, contributing to a mixed sentiment profile.
Fjarde AP Fonden increased its stake in Bristol Myers Squibb (NYSE:BMY) by 21.5% during the first quarter, purchasing an additional 105,200 shares to hold a total of 595,006 shares valued at approximately $36 million. This move aligns with other major institutional investors who also expanded their positions in the biopharmaceutical giant during the fourth quarter, including Vanguard Group, State Street Corp, Geode Capital Management, Norges Bank, and AQR Capital Management.
Institutional ownership of Bristol Myers Squibb stands at 76.41%, reflecting continued confidence from large asset managers. The company currently trades with a market capitalization of $118.54 billion and a price-to-earnings ratio of 16.31. Analyst consensus ratings remain mixed, with eight buy ratings, ten hold ratings, and one sell rating, resulting in a consensus target price of $61.31.
Bristol Myers Squibb recently announced a quarterly dividend of $0.63 per share, payable on August 3rd to shareholders of record as of July 2nd. This dividend represents an annualized yield of 4.3% with a payout ratio of 70.79%. The stock has seen recent analyst attention, including a price target increase from HSBC and a strong-buy upgrade from Wall Street Zen.
📈 Fjarde AP Fonden added 105,200 shares, holding 595,006 total.
🏦 Vanguard Group owns 198.7M shares worth over $10.7 billion.
💰 Norges Bank started a new $1.95 billion position in Q4.
🚀 AQR Capital boosted stake by 172.6% to 25.8 million shares.
📉 Institutional investors hold 76.41% of Bristol Myers Squibb stock.
📈 Fjarde AP Fonden increased its BMY stake by 21.5% in Q1, adding 105,200 shares to a total holding of 595,006 shares.
🏦 Vanguard Group lifted its position by 1.4% in Q4, now owning 198.7 million shares worth over $10.7 billion.
📊 State Street Corp grew its BMY holdings by 1.4% in the fourth quarter to a total value of $5.28 billion.
🚀 Geode Capital Management LLC increased its stake by 13.1% in Q4, acquiring an additional 6 million shares.
💰 Norges Bank initiated a new position in BMY valued at approximately $1.95 billion during the fourth quarter.
📈 AQR Capital Management significantly boosted its exposure, lifting its position by 172.6% to own 25.8 million shares.
📉 Institutional investors collectively hold 76.41% of Bristol Myers Squibb's outstanding stock.
💵 The company declared a quarterly dividend of $0.63 per share with an ex-dividend date of July 2nd.
🎯 HSBC raised its price target for BMY from $53.00 to $60.00 while maintaining a hold rating.
⭐ Wall Street Zen upgraded Bristol Myers Squibb from a buy to a strong-buy rating in late June.
📊 Guggenheim reiterated a buy rating and set a price target of $72.00 for the biopharmaceutical stock.
📉 The consensus analyst rating is hold with a mean price target of $61.31 according to MarketBeat.
Bullish Signals
Major institutions increased stakes including Fjarde AP Fonden and Vanguard.
Stock offers 4.3% dividend yield with 70.79% payout ratio.
HSBC raised price objective from $53.00 to $60.00.
Wall Street Zen upgraded stock to strong-buy rating.
Guggenheim maintains buy rating with $72.00 price target.
Risk Factors
Consensus hold rating suggests limited immediate upside potential.
One of eleven analyst ratings is a sell.
Bullish Signals
Major institutional investors including Fjarde AP Fonden, Vanguard, State Street, Geode Capital, Norges Bank, and AQR Capital Management all increased their stakes in the company during recent quarters.
The stock offers a dividend yield of 4.3% with a payout ratio of 70.79%, providing income to shareholders.
HSBC raised its price objective from $53.00 to $60.00, indicating improved valuation expectations.
Wall Street Zen upgraded the stock to a strong-buy rating, signaling confidence in future performance.
Guggenheim maintains a buy rating with a specific price target of $72.00.
Risk Factors
The consensus analyst rating is hold, suggesting that while the company is stable, there may be limited immediate upside potential according to Wall Street analysts.
Only one sell rating exists among eleven total ratings, indicating some analysts remain cautious about the stock's near-term prospects.
Bristol-Myers Squibb (NYSE:BMY) is approaching its ex-dividend date of July 2nd, with the dividend payment scheduled for August 3rd. The upcoming quarterly dividend is set at US$0.63 per share, following a total annual distribution of US$2.52 over the last 12 months. This results in a trailing yield of approximately 4.4% based on the current share price of US$57.52.
The company demonstrates dividend sustainability by covering its payouts with both earnings and free cash flow. Last year, Bristol-Myers Squibb paid out roughly 70% of its earnings and only 43% of its free cash flow toward dividends. Historical data shows steady earnings per share growth averaging 9.3% over the last five years, while dividend increases have averaged 5.5% annually over the past decade.
Analysts note that while the company effectively rewards shareholders with a sustainable dividend, it is unlikely to reinvest heavily in business expansion due to the high payout ratio relative to earnings. The stock is viewed as an 'okay' investment for income but not necessarily a standout growth opportunity without significant changes in earnings or valuation.
📅 Ex-dividend July 2nd; $0.63 payable August 3rd.
💰 4.4% yield on current price of $57.52.
📈 EPS grew 9.3% annually over last five years.
💵 Dividends covered by 70% of earnings and 43% of FCF.
📉 Average dividend increase of 5.5% per year for decade.
📅 BMY stock will trade ex-dividend on July 2nd, with the US$0.63 dividend payable on August 3rd.
💰 The trailing dividend yield is 4.4% based on a current share price of US$57.52.
📈 Earnings per share have grown by an average of 9.3% over the last five years.
💵 Dividends are covered by 70% of earnings and only 43% of free cash flow from the prior year.
📉 The company has increased its dividend by approximately 5.5% annually on average over the last decade.
⚠️ High payout ratio relative to earnings suggests limited capacity for heavy business reinvestment.
Bullish Signals
Upcoming dividend of US$0.63 offers 4.4% trailing yield.
Dividends covered by profits (70%) and free cash flow (43%).
EPS grew 9.3% annually over last five years.
Dividends increased 5.5% annually over past 10 years.
Risk Factors
High payout ratio limits business growth reinvestment.
Janney Montgomery Scott LLC increased its stake in Bristol Myers Squibb (NYSE:BMY) by 6.8% in the first quarter, purchasing 49,310 shares to bring total holdings to 770,244 shares valued at approximately $46.7 million. Other institutional investors also adjusted positions, with Horizon Bancorp increasing its stake by 22.1% and several wealth management firms adding new or increased positions, while company insiders own a negligible 0.05% of the stock.
Bristol Myers Squibb reported better-than-expected quarterly financial results, posting earnings per share (EPS) of $1.58 against a consensus estimate of $1.42 and revenue of $11.49 billion versus an expected $10.93 billion. The company achieved a net margin of 15.01% and a return on equity of 64.87%, with revenue growing 2.6% year-over-year. Additionally, the firm declared a quarterly dividend of $0.63 per share, payable on August 3rd to shareholders of record on July 2nd.
Analyst sentiment remains mixed but generally positive regarding the company's fundamentals. UBS restated a 'buy' rating, Wall Street Zen upgraded the stock to 'strong-buy', and HSBC raised its price objective from $53.00 to $60.00, though Bank of America lowered its target to $67.00. The consensus analyst rating is currently 'Hold' with an average price target of $61.31, while the stock trades at a P/E ratio of 16.14 and a market capitalization of $117.31 billion.
📈 Janney Montgomery Scott bought 49,310 BMY shares for $46.7M.
💰 Bristol Myers Squibb beat earnings with $1.58 EPS and $11.49B revenue.
📊 Company reported 15.01% net margin and 64.87% return on equity.
💵 Quarterly dividend declared at $0.63 per share for 4.4% yield.
📉 EVP David V. Elkins sold 30,000 shares, reducing position by 15.85%.
📈 Janney Montgomery Scott LLC increased its BMY stake by 6.8% in Q1, buying 49,310 shares for a total holding value of $46.7 million.
💰 Bristol Myers Squibb beat earnings expectations with $1.58 EPS and $11.49 billion revenue, surpassing analyst consensus estimates.
📊 The company reported strong profitability metrics including a 15.01% net margin and a 64.87% return on equity.
💵 A quarterly dividend of $0.63 per share was declared, offering a yield of 4.4% to shareholders.
📉 EVP David V. Elkins sold 30,000 shares in early April, reducing his personal position by 15.85%.
🏦 Institutional ownership remains high at 76.41%, with multiple firms like Horizon Bancorp and Cornerstone Wealth increasing stakes.
📝 Analyst ratings are mixed; UBS and Wall Street Zen maintain or upgrade 'buy' ratings, while Bank of America lowered its price target.
🎯 The consensus analyst price target is $61.31, with the stock currently trading at a P/E ratio of 16.14.
📈 Revenue grew 2.6% year-over-year, demonstrating continued top-line growth in the biopharmaceutical sector.
Bullish Signals
EPS beat estimates at $1.58 vs $1.42 consensus.
Revenue hit $11.49B, up 2.6% year-over-year.
Institutional confidence rises as Janney adds 6.8% position.
Wall Street Zen upgrades rating to strong-buy.
HSBC raises price target from $53 to $60.
Quarterly dividend of $0.63 offers 4.4% yield.
Risk Factors
David V. Elkins sold 30,000 shares, reducing stake by 15.85%.
Bank of America lowered price objective from $68.00 to $67.00.
Citigroup reissued neutral rating on the stock.
Consensus analyst rating is Hold with limited upside potential.
Bullish Signals
Bristol Myers Squibb reported earnings per share of $1.58, which beat analyst consensus estimates of $1.42 by $0.16.
The company generated revenue of $11.49 billion, exceeding the expected $10.93 billion and showing a 2.6% year-over-year increase.
Janney Montgomery Scott LLC increased its position by 6.8%, signaling institutional confidence in the stock's prospects.
Wall Street Zen upgraded its rating on BMY from 'buy' to 'strong-buy', reflecting improved analyst sentiment.
HSBC raised its price objective for Bristol Myers Squibb from $53.00 to $60.00, indicating a bullish outlook on valuation.
The company declared a quarterly dividend of $0.63 per share, providing a 4.4% yield to investors.
Risk Factors
EVP David V. Elkins sold 30,000 shares in early April, reducing his personal stake by 15.85%.
Bank of America lowered its price objective for Bristol Myers Squibb from $68.00 to $67.00.
Citigroup reissued a 'neutral' rating on the stock, contributing to a mixed analyst consensus.
The consensus analyst rating is currently 'Hold', suggesting some analysts see limited upside potential at current levels.
Wall Street Zen upgraded Bristol Myers Squibb (NYSE:BMY) to a 'strong-buy' rating, joining a mixed consensus of eight buy ratings, ten holds, and one sell. The stock currently trades with an average analyst target price of $61.31, reflecting varied sentiment among major institutions including recent downgrades from Bank of America and reaffirmations from Citigroup.
The company reported strong quarterly financial results for the quarter ended April 30th, beating consensus estimates significantly. Bristol Myers Squibb generated revenue of $11.49 billion, surpassing analyst expectations of $10.93 billion, while posting earnings per share (EPS) of $1.58 against a consensus of $1.42. The firm achieved a net margin of 15.01% and a return on equity of 64.87%, with revenue growing 2.6% year-over-year.
Looking ahead, Bristol Myers Squibb has set full-year 2026 EPS guidance between $6.05 and $6.35, which aligns closely with the average analyst prediction of $6.32 for the current fiscal year. Recent insider activity includes a notable sale by EVP David V. Elkins, who reduced his holdings by 15.85% in April, while several hedge funds have increased their stakes in the first quarter.
📈 Wall Street Zen upgraded stock to 'strong-buy' rating.
💰 Q1 EPS beat estimates at $1.58 per share.
📊 Revenue grew 2.6% YoY to reach $11.49 billion.
🔮 FY 2026 EPS guidance aligns with analyst consensus.
🏦 Hedge funds increased positions while EVP sold shares.
📈 Wall Street Zen upgraded Bristol Myers Squibb to a 'strong-buy' rating, adding to eight existing buy ratings from major analysts.
💰 The company reported Q1 EPS of $1.58, beating the consensus estimate of $1.42 by $0.16.
📊 Revenue reached $11.49 billion for the quarter, exceeding analyst estimates of $10.93 billion and growing 2.6% year-over-year.
🎯 Bristol Myers Squibb achieved a net margin of 15.01% and a return on equity of 64.87% during the reported period.
🔮 The company provided FY 2026 EPS guidance ranging from $6.05 to $6.35, aligning with analyst consensus of $6.32.
📉 EVP David V. Elkins sold 30,000 shares in April for a total transaction value of $1,850,100.
🏦 Hedge fund activity shows mixed signals, with NewEdge Advisors increasing its position by 12.9% while Basecamp Wealth Advisors lifted holdings by 13.8%.
📉 The current consensus analyst rating for the stock remains 'Hold' with a target price of $61.31.
💊 Bristol Myers Squibb focuses its portfolio on oncology, hematology, immunology, and cardiovascular disease through small molecules and biologics.
Bullish Signals
EPS beat at $1.58 vs $1.42 estimate.
Revenue hit $11.49B above $10.93B forecast.
Net margin reached 15.01% with ROE of 64.87%.
Upgraded to 'strong-buy' by Wall Street Zen.
FY 2026 EPS guidance aligns at $6.05-$6.35.
Risk Factors
Bank of America lowered price target from $68.00 to $67.00.
EVP David V. Elkins reduced ownership by 15.85% in April.
Bullish Signals
Bristol Myers Squibb beat quarterly earnings expectations with EPS of $1.58 versus the consensus estimate of $1.42.
Revenue of $11.49 billion exceeded analyst forecasts of $10.93 billion, demonstrating strong commercial performance.
The company delivered a robust net margin of 15.01% and a high return on equity of 64.87%.
Wall Street Zen upgraded the stock to 'strong-buy', signaling increased institutional confidence in the company's prospects.
FY 2026 guidance of $6.05-$6.35 EPS aligns well with analyst consensus, suggesting stable future expectations.
Risk Factors
Bank of America lowered its price target from $68.00 to $67.00, indicating some caution among analysts.
EVP David V. Elkins sold a significant portion of his holdings, reducing ownership by 15.85% in April.
Bristol-Myers Squibb (BMY) is currently trading at $54.70, reflecting a recent 30-day decline of 8.01% despite a 22.41% total shareholder return over the past year. The company has declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, to shareholders of record on July 2, 2026, offering a yield of approximately 4.6%.
Analysts at Simply Wall St estimate BMY's fair value at $62.96, suggesting the stock is undervalued by roughly 13%. This valuation gap is attributed to a robust late-stage pipeline, strategic partnerships with entities like BioNTech and Philochem, and potential for label expansions that could offset upcoming patent expiries for major brands such as Eliquis and Opdivo.
Despite the bullish fair value narrative, the stock faces mixed signals regarding valuation metrics. The current P/E ratio of 15.4x is slightly above the US pharmaceuticals industry average of 14.9x but below a calculated fair ratio of 18.6x and peer averages of 21.7x. Investors must weigh these potential upside drivers against significant risks including patent cliffs, pricing pressure in the core U.S. market, and shifting revenue mix dynamics.
📈 BMY trades at $54.70 with a 22.41% one-year return.
💰 Quarterly dividend of $0.63 yields approximately 4.6%.
📊 Analysts estimate fair value of $62.96, implying 13% undervaluation.
🔬 Partnerships expand pipeline to offset patent expiries for Eliquis and Opdivo.
⚠️ Risks include patent cliffs and U.S. pricing pressure.
📈 BMY stock is trading at $54.70 with a recent 30-day return of -8.01% but a 1-year total shareholder return of 22.41%.
💰 The company declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, yielding approximately 4.6%.
📊 Analysts estimate a fair value of $62.96, implying the stock is undervalued by roughly 13% based on discounted cash flow models.
🔬 Strategic partnerships with BioNTech and Philochem aim to expand pipeline breadth and offset patent expiries for key drugs like Eliquis and Opdivo.
⚖️ The current P/E ratio of 15.4x sits between the industry average of 14.9x and a fair peer-adjusted ratio of 18.6x.
⚠️ Significant risks include patent cliffs for major revenue drivers and ongoing pressure on pricing and margins in the U.S. market.
Bullish Signals
4.6% dividend yield with $0.63 quarterly payout.
Risk Factors
Patent cliffs for Eliquis and Opdivo pose risks.
P/E ratio of 15.4x exceeds industry average of 14.9x.
Bullish Signals
The company offers a 4.6% dividend yield with a declared quarterly payout of $0.63 per share.
Analyst fair value models suggest BMY is undervalued by approximately 13% relative to a target price of $62.96.
A robust late-stage pipeline and strategic partnerships are expected to support top-line growth and offset patent expiries.
Risk Factors
The stock faces meaningful risks from patent cliffs associated with key drugs like Eliquis and Opdivo.
Valuation metrics show mixed signals, with the current P/E ratio of 15.4x exceeding the industry average of 14.9x.
Corient Private Wealth LLC increased its stake in Bristol Myers Squibb (NYSE:BMY) by 7.5% during the fourth quarter, acquiring an additional 33,958 shares to hold a total of 489,348 shares valued at $26.4 million. Several other institutional investors also adjusted their positions, including Swiss RE Ltd., Darwin Wealth Management LLC, and Physician Wealth Advisors Inc., which increased its stake by 73.5%. Collectively, institutional investors own 76.41% of the company's outstanding stock.
Analyst sentiment remains mixed but generally positive, with a consensus rating of 'Hold' and an average price target of $61.31. Major firms like UBS Group and Guggenheim maintain 'Buy' ratings, while HSBC raised its price target to $60.00. Conversely, Wall Street Zen downgraded the stock from 'strong-buy' to 'buy', and Bank of America lowered its price objective to $67.00. The company recently announced a quarterly dividend of $0.63 per share, payable on August 3rd to shareholders of record as of July 2nd.
Financial metrics indicate Bristol Myers Squibb has a market capitalization of $111.62 billion and a P/E ratio of 15.35. The stock currently trades at $54.66, sitting below its 50-day moving average of $57.25 but above its 52-week low of $42.52. Key financial ratios include a current ratio of 1.42, a quick ratio of 1.28, and a debt-to-equity ratio of 2.10. EVP David V. Elkins sold 30,000 shares in April, reducing his personal holding by 15.85%.
Bristol-Myers Squibb (BMY) shares are trading at $54.70, reflecting a recent 30-day decline of 8.01% despite a 22.41% total shareholder return over the past year. The company recently declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, to shareholders of record on July 2, 2026, offering a yield of approximately 4.6%.
Analysts at Simply Wall St estimate the stock's fair value at $62.96, suggesting it is undervalued by roughly 13%. This valuation gap is attributed to a robust late-stage pipeline, strategic partnerships with entities like BioNTech and Philochem, and potential for label expansions that could offset upcoming patent expiries for major brands such as Eliquis and Opdivo.
Despite the bullish fair value estimate, the stock presents mixed signals regarding valuation metrics. The current P/E ratio of 15.4x sits slightly above the US pharmaceuticals industry average of 14.9x but remains below a calculated fair ratio of 18.6x and peer averages of 21.7x. Investors must weigh these potential upside drivers against significant risks including patent cliffs, pricing pressure in the core U.S. market, and shifting revenue mix dynamics.
📈 BMY shares trade at $54.70 with a 1-year return of 22.41%.
💰 Quarterly dividend is $0.63 per share yielding approximately 4.6%.
🎯 Analysts estimate fair value of $62.96, implying roughly 13% undervaluation.
🔬 Strategic partnerships aim to offset patent expiries for key drugs.
⚠️ Risks include patent cliffs and pressure on U.S. pricing margins.
📈 Bristol-Myers Squibb (BMY) shares are trading at $54.70 with a recent 30-day return of -8.01% but a 1-year total shareholder return of 22.41%.
💰 The company declared a quarterly dividend of $0.63 per share, payable on August 3, 2026, to shareholders of record on July 2, 2026.
📊 The stock offers a current dividend yield of approximately 4.6% based on the latest share price.
🎯 Analysts estimate a fair value of $62.96, implying the stock is undervalued by roughly 13% or an intrinsic discount of 54.52%.
🔬 The company's late-stage pipeline and strategic partnerships with BioNTech and Philochem aim to offset patent expiries for key drugs like Eliquis and Opdivo.
⚖️ The current P/E ratio of 15.4x is slightly above the industry average of 14.9x but below a fair ratio of 18.6x and peer averages of 21.7x.
⚠️ Significant risks include patent cliffs for major brands, pressure on pricing and margins in the core U.S. market, and potential shifts in revenue mix.
Bullish Signals
Undervalued by 13% with fair value of $62.96.
Robust pipeline supports future regulatory approvals and label expansions.
Solid 4.6% dividend yield with quarterly payout of $0.63.
Delivered 22.41% total shareholder return over past year.
Risk Factors
Patent cliffs for Eliquis and Opdivo pose meaningful risks.
P/E ratio of 15.4x exceeds industry average of 14.9x.
Bullish Signals
The stock is estimated to be undervalued by approximately 13% with a fair value of $62.96 compared to the current price of $54.70.
A robust late-stage pipeline and strategic partnerships are expected to support future regulatory approvals and label expansions, helping offset patent expiries.
The company offers a solid 4.6% dividend yield with a declared quarterly payout of $0.63 per share.
The stock has delivered a strong 22.41% total shareholder return over the past year despite recent cooling momentum.
Risk Factors
The company faces meaningful risks from patent cliffs associated with key drugs like Eliquis and Opdivo.
Valuation metrics show mixed signals, with the current P/E ratio of 15.4x sitting above the industry average of 14.9x.
Bristol-Myers Squibb (BMY) stock is currently trading at $56.24, reflecting a mixed performance with a year-to-date return of 5.2% and a recent 90-day decline of 5.81%. The company has recently expanded its kidney cancer trial, the ROSETTA RCC-208 study, through a clinical collaboration with Arcus Biosciences to add new casdatifan arms.
Analysts project that BMY's revenue will decrease by 6.2% annually over the next three years, while profit margins are expected to improve significantly from 15.0% today to 21.5% in three years. Based on these assumptions regarding earnings paths and future multiples, a popular valuation narrative suggests a fair value of $62.96, indicating the stock is undervalued by approximately 10.7%.
Despite the optimistic valuation outlook, the company faces headwinds including upcoming patent expiries on key drugs and the risk that new launches or pipeline assets may underperform expectations. The current P/E ratio of 15.8x sits between the US pharmaceutical industry average of 15.1x and peer group average of 22.3x, suggesting a complex valuation landscape with both risks and opportunities.
🔬 Bristol-Myers Squibb expands kidney cancer trial with Arcus Biosciences.
💰 Stock trades at $56.24 with 4.5% dividend yield and value score of 4.
📉 Analysts forecast annual revenue decreases of 6.2% over next three years.
📈 Profit margins projected to rise from 15.0% to 21.5% in three years.
💵 Fair value estimated at $62.96, implying 10.7% undervaluation.
🔬 Bristol-Myers Squibb expanded its kidney cancer trial (ROSETTA RCC-208) via a collaboration with Arcus Biosciences to include new casdatifan arms.
💰 The stock trades at $56.24, offering a 4.5% dividend yield and a value score of 4.
📉 Analysts forecast annual revenue decreases of 6.2% over the next three years.
📈 Profit margins are projected to rise from 15.0% currently to 21.5% in three years.
💵 A widely followed valuation model estimates a fair value of $62.96, implying a 10.7% undervaluation.
⚠️ The company faces risks from upcoming patent expiries on key drugs and potential underperformance of new launches.
📊 The current P/E ratio of 15.8x is higher than the industry average (15.1x) but lower than peers (22.3x).
Bullish Signals
Clinical collaboration expands kidney cancer trial pipeline.
Profit margins forecast to rise from 15.0% to 21.5%.
Undervalued by 10.7% with fair value target of $62.96.
Attractive 4.5% dividend yield provides income support.
Risk Factors
Revenue projected to drop 6.2% annually for three years.
Key drug patents face imminent expiration pressures.
New launches may underperform market expectations.
Bullish Signals
The company has secured a clinical collaboration with Arcus Biosciences to expand its kidney cancer trial, signaling continued pipeline development.
Analysts forecast a significant improvement in profit margins, rising from 15.0% to 21.5% over the next three years.
Valuation models suggest the stock is undervalued by 10.7% with a fair value target of $62.96 versus the current price of $56.24.
The stock offers an attractive 4.5% dividend yield, providing income support for investors.
Risk Factors
Analysts project that revenue will decrease by 6.2% annually over the next three years.
The company faces real pressure from upcoming patent expiries on its key drugs.
There is a risk that newer launches and pipeline assets could underperform market expectations.
Bristol-Myers Squibb's growth portfolio has surpassed its legacy business in revenue for the first time during Q1 2026, challenging the prevailing market narrative that the company is a "melting ice cube" solely reliant on declining Revlimid and Eliquis sales. The article identifies four specific near-term catalysts within the pipeline—iberdomide, mezigdomide, milvexian, and Cobenfy—that could drive a stock re-rating within seven months of the report's publication.
Valuation analysis suggests the stock is mispriced relative to its fundamentals; even under bearish consensus forecasts, a discounted cash flow (DCF) model supports a target price of $68.5 per share, which represents approximately 20% upside from current levels with downside protection. The company currently trades at a 9x forward earnings multiple and offers a 4.35% dividend yield, positioning it as a bridge to future growth rather than facing an immediate cliff in revenue generation.
📉 Legacy revenue fears persist as Growth Portfolio surpasses Legacy in Q1 2026.
💊 Four pipeline catalysts could force a stock re-rating within seven months.
📈 DCF model supports $68.5 valuation, offering 20% upside with downside protection.
📉 Bristol-Myers Squibb (BMY) is currently viewed by the market as a "melting ice cube" due to fears that its legacy revenue stream is collapsing.
📊 The company's Growth Portfolio has officially surpassed its Legacy Portfolio in terms of revenue for Q1 2026.
💊 Four near-term pipeline catalysts are identified: iberdomide, mezigdomide, milvexian, and Cobenfy.
⏳ These four new drugs could potentially force a stock re-rating within the next seven months.
📈 Even under bearish consensus forecasts, a Discounted Cash Flow (DCF) model supports a valuation of $68.5 per share.
💰 This supported valuation represents approximately 20% upside from current price levels with downside protection.
📉 BMY is trading at a 9x forward earnings multiple and offers a dividend yield of 4.35%.
🛡️ The investment thesis suggests the stock provides free pipeline optionality rather than facing a cliff after Eliquis.
🧬 Revlimid has fallen off its peak, leading to market concerns that Eliquis will be the next major revenue driver.
📊 The author utilizes a data analytics and SQL background to analyze market trends and patterns for this article.
🤝 The author discloses no current stock positions or plans to initiate positions in the mentioned companies within 72 hours.
⚠️ Seeking Alpha notes that past performance does not guarantee future results and this is not investment advice.
Four near-term catalysts like iberdomide could drive re-rating within seven months.
Dow Jones DCF model supports $68.5/share valuation, 20% above current levels.
BMY offers downside protection with 9x forward earnings and 4.35% yield.
Company provides pipeline optionality and financial bridge beyond Eliquis.
Risk Factors
Three-year Revlimid fear creates bearish sentiment for Eliquis.
Stock mispriced as melting ice cube despite Q1 2026 growth.
$68.5 valuation relies on bearish forecasts and decline risks.
Future beyond Eliquis is a bridge, not a cliff.
Reliance on four catalysts implies lack of organic growth.
Bullish Signals
Bristol Myers Squibb's Growth Portfolio revenues surpassed Legacy revenues in Q1 2026, signaling a successful transition away from reliance on Revlimid.
The company has four near-term pipeline catalysts including iberdomide, mezigdomide, milvexian, and Cobenfy that could drive a stock re-rating within seven months.
Even using bearish consensus forecasts, the discounted cash flow (DCF) model supports a $68.5/share valuation, which is approximately 20% above current levels.
BMY offers downside protection with a 9x forward earnings multiple and a 4.35% dividend yield.
The company provides free pipeline optionality and a financial bridge beyond its key drug Eliquis, rather than facing a cliff.
Risk Factors
The market narrative has been dominated for three years by the fear that Revlimid fell off a cliff, creating a bearish sentiment that Eliquis will be the next major revenue driver.
Despite the growth portfolio surpassing legacy revenues in Q1 2026, the article explicitly states the stock is 'mispriced as a melting ice cube', indicating significant underlying fragility and potential value erosion.
The valuation support of $68.5/share relies on bearish consensus forecasts, suggesting that even under pessimistic assumptions, the market may be undervaluing the risk of further declines.
The company's future beyond Eliquis is described as a 'bridge' rather than a 'cliff', implying uncertainty and potential instability in long-term revenue sustainability.
The reliance on four near-term catalysts (iberdomide, mezigdomide, milvexian, and Cobenfy) to force a re-rating within seven months suggests the current business model lacks sufficient organic growth drivers without these specific bets.
BioNTech and Bristol Myers Squibb have announced encouraging interim Phase 2 data from the global ROSETTA Lung-02 clinical trial for pumitamig, a PD-L1xVEGF-A bispecific immunomodulator. The combination of pumitamig with chemotherapy demonstrated robust antitumor activity in patients with previously untreated advanced non-small cell lung cancer (NSCLC) across all evaluated dose levels and PD-L1 expression subtypes. At the interim analysis with an April 13, 2026 data cut-off, treatment showed high efficacy regardless of tumor subtype or programmed death-ligand 1 status.
Specifically, among response-evaluable patients, pumitamig plus chemotherapy achieved a confirmed objective response rate (cORR) of 57.1% in non-squamous NSCLC and 68.4% in squamous NSCLC at the interim analysis. Higher response rates were observed at the lower dose level, with a cORR of 63.6% for non-squamous NSCLC and 72.7% for squamous NSCLC. The efficacy was consistent across patients with less than 1%, between 1-49%, and greater than or equal to 50% PD-L1 tumor proportion score (TPS), reaching 100% response in the TPS ≥ 50 group at the lower dose. Furthermore, the treatment demonstrated a disease control rate of 100% and showed a manageable safety profile with Grade 3 treatment-related adverse events reported in 23.3% of patients attributed to pumitamig, leading to discontinuation in only 9.3% of cases.
The companies are advancing a comprehensive global Phase 3 development program for pumitamig in NSCLC following these positive results. In addition to the actively enrolling pivotal Phase 3 part of the ROSETTA Lung-02 trial, two additional global Phase 3 trials are underway, including ROSETTA Lung-201 comparing pumitamig to durvalumab following concurrent chemoradiation in unresectable stage III NSCLC and ROSETTA Lung-202 evaluating pumitamig against pembrolizumab as a first-line treatment for advanced PD-L1 ≥ 50% NSCLC. These results support the continued investigation of pumitamig's potential to set a new standard of care by enhancing anti-tumor responses in one of oncology's most challenging indications.
📈 Interim Phase 2 data shows robust activity with up to 72.7% response in squamous NSCLC.
🎯 High efficacy observed across all PD-L1 subgroups including low expression patients (TPS < 1%).
💊 Drug maintains manageable safety with only 9.3% discontinuation and limited severe adverse events.
🌍 Data presented at 2026 ASCO based on April 2026 cut-off for global Phase 3 advancement.
🔄 Multiple pivotal trials enrolling to compare pumitamig against standard-of-care immunotherapies.
📈 BioNTech and Bristol Myers Squibb announced encouraging interim Phase 2 data for their bispecific drug pumitamig in non-small cell lung cancer.
💉 The investigational PD-L1xVEGF-A bispecific immunomodulator shows robust activity when combined with chemotherapy in first-line treatment.
📊 Confirmed objective response rates reached up to 72.7% in squamous NSCLC and 63.6% in non-squamous NSCLC at the lower dose level.
🎯 High efficacy was observed across all PD-L1 expression subgroups, including patients with low expression (TPS < 1%).
💊 The drug demonstrated a manageable safety profile with a low treatment discontinuation rate and limited high-grade immune-related adverse events.
🌍 The data were presented as an oral session at the 2026 ASCO Annual Meeting in Chicago based on an April 2026 data cut-off.
🏗️ Pumitamig is advancing through a global Phase 3 development program including the pivotal ROSETTA Lung-02 trial currently recruiting for its final part.
🔄 Two additional global Phase 3 trials, ROSETTA Lung-201 and ROSETTA Lung-202, are enrolling patients to compare pumitamig against standard-of-care therapies like durvalumab and pembrolizumab.
💬 Lead investigator Solange Peters stated that targeting the PD-L1 pathway alone is insufficient for durable responses in advanced disease.
🤝 Co-founder Özlem Türeci highlighted the potential of the bispecific molecule to enhance anti-tumor responses by simultaneously targeting PD-L1 and VEGF-A.
🎯 Senior Vice President Anne Kerber emphasized the goal of improving outcomes for patients left behind by current therapies in this challenging disease.
⚠️ Grade 3 or higher treatment-related adverse events occurred in 48.8% of patients, though only one severe bleeding event was recorded.
📉 Discontinuation due to pumitamig-related adverse events was reported in 9.3% of the patients studied during this interim analysis.
🧬 The Phase 2 portion of the trial evaluated two different dose levels, with higher efficacy noted at the lower dose compared to the higher one.
🩺 Disease control rate (DCR) reached 100% in the patient population evaluated, indicating strong stabilization of the disease for all responders.
Bullish Signals
Robust antitumor activity in NSCLC across all PD-L1 levels.
Lower doses achieved high response rates: 63.6% non-squamous and 72.7% squamous.
Perfect interim disease control rate of 100% in all patients.
Manageable safety with only 9.3% discontinuation rate due to low adverse events.
Advancing global Phase 3 program with two additional pivotal trials enrolling.
Risk Factors
Only rapid oral abstract presented; full publication pending.
100% response limited to narrow TPS ≥ 50% subgroup.
9.3% discontinued due to pumitamig toxicity concerns.
Bullish Signals
Pumitamig demonstrated robust and consistent antitumor activity in first-line non-small cell lung cancer across all PD-L1 expression levels, including TPS < 1%, TPS 1-49%, and TPS ≥ 50%.
The lower dose of pumitamig plus chemotherapy achieved the highest confirmed objective response rates, with 63.6% in non-squamous subtypes and an exceptional 72.7% in squamous subtypes.
At the interim analysis, the drug combination showed a perfect disease control rate (DCR) of 100% across all evaluated patients.
Pumitamig exhibited a manageable safety profile with only a low discontinuation rate of 9.3%, driven by four treatment-related adverse events in 48.8% of patients.
The company is advancing the asset through a comprehensive global Phase 3 development program, with two additional pivotal Phase 3 trials currently enrolling alongside the ROSETTA Lung-02 trial.
BioNTech and Bristol Myers Squibb are accelerating development with a broad registrational plan covering multiple disease stages, including new combination trials with antibody-drug conjugates.
Risk Factors
The interim data from the ROSETTA Lung-02 trial was presented only as a rapid oral abstract at the ASCO Annual Meeting, indicating that full publication has not yet occurred.
Although the confirmed objective response rate reached 100% for patients with TPS ≥ 50%, this represents a very narrow subgroup compared to broader populations where efficacy is lower (47.6%).
Bleeding events occurred in 20.9% of patients, which poses safety concerns given that the mechanism involves inhibiting VEGF-A, typically associated with vascular risks.
Grade ≥ 3 treatment-related adverse events were reported in 48.8% of patients, representing a significant burden for advanced cancer patients already facing toxicity from chemotherapy.
Four patients (9.3%) discontinued treatment due to pumitamig-related adverse events, raising questions about long-term tolerability at the interim analysis stage.
C4 Therapeutics stock rallied on Friday, reaching a 52-week high after Bristol-Myers Squibb released positive late-stage clinical trial data for its new treatment targeting multiple myeloma, a type of blood cancer. C4 shares surged due to the similarity between Bristol-Myers' drug and C4's own lead asset, which is also in development for treating the same condition. The news provided validation for C4 Therapeutics' pipeline as investors reacted positively to the comparative success of a larger pharmaceutical partner's similar compound.
📈 C4 Therapeutics stock hit a 52-week high on positive BMS trial data.
💊 Strong survival results in late-stage multiple myeloma trials drove the surge.
🔬 Bristol-Myers Squibb's treatment resembles C4's lead candidate asset closely.
📈 C4 Therapeutics (CCCC) stock reached a 52-week high on Friday following positive news from Bristol-Myers Squibb.
💊 The price surge was driven by strong survival data generated in a late-stage trial for multiple myeloma, a blood cancer.
🔬 Bristol-Myers Squibb's treatment is similar to C4 Therapeutics' lead candidate asset.
📅 The news was published on May 29, 2026, by Seeking Alpha News Editor Dulan Lokuwithana.
🏢 Bristol-Myers Squibb trades under the ticker symbol BMY on the NYSE.
🧬 C4 Therapeutics trades under the ticker symbol CCCC on the NASDAQ.
📊 The article is categorized under "On the Move" financial news.
Bullish Signals
C4 Therapeutics (CCCC) hit 52-week high after Bristol-Myers Squibb news.
Bristol-Myers Squibb drug validated CCCC's lead candidate with survival data.
Risk Factors
Article lacks negative aspects, risks, or downside catalysts.
Focuses only on positive developments for BMY and CCCC.
Bullish Signals
C4 Therapeutics (CCCC) stock reached a 52-week high following positive news from Bristol-Myers Squibb.
Bristol-Myers Squibb's multiple myeloma drug generated impressive survival data in a late-stage trial, validating the therapeutic approach for CCCC's lead candidate.
Risk Factors
The article focuses entirely on positive developments for Bristol-Myers Squibb (BMY) and C4 Therapeutics (CCCC), noting that CCCC reached a 52-week high.
No negative aspects, risks, or downside catalysts are mentioned in the provided text.
Published on May 2, 2026, this article argues that Bristol-Myers Squibb Company (BMY) is currently undervalued by the market despite facing a significant patent cliff in 2026. The stock is trading at a discounted forward price-to-earnings ratio of 9.4x, a valuation driven largely by investor fears regarding expiring patents. However, the author contends that the company is robustly equipped to navigate this challenge with a strong pipeline and substantial CAR-T optionality that remains largely unpriced in the current valuation model. Underlying these risks are compelling fundamentals, including a 15-20% base case upside potential combined with a 4.3% dividend yield.
The near-term catalyst stack for BMY in 2026 includes several key compounds: Milvexian, Iberdomide, Cobenfy, and Sotyktu. The article suggests that the success of any one of these assets could trigger a significant rerating of the stock, pushing its forward P/E multiple from current levels to a range of 10x-11x. Beyond these immediate drivers, BMY's advanced CAR-T program, particularly zola-cel targeted for autoimmune indications, is highlighted as a major source of long-term optionality that offers further upside potential beyond the current market consensus.
The author of the piece, Joseph "Kade" Minton, identifies himself as an engineering physics and applied mathematics graduate who now works in environmental and industrial compliance. He utilizes quantitative models incorporating concepts such as differential equations and linear algebra, while balancing them with macroeconomic winds and historical regulatory precedent to identify speculative growth stocks he believes are undervalued. His broader thesis posits that the biotech sector is approaching a golden era characterized by revolutionary breakthroughs in treating diseases like cancer, Alzheimer's, and autoimmune disorders, alongside advancements in technology such as fusion energy and solid-state batteries.
The author discloses holding beneficial long positions in shares of KYTX, RNAC, CABA, and CRBU, though he states he does not hold a business relationship with any company mentioned in the text except for those specific holdings or through Seeking Alpha. Seeking Alpha's standard disclaimers note that past performance does not guarantee future results and that the article expresses the author's own opinions rather than the views of the platform as an investment advisor. The content explicitly avoids giving recommendations or advice on investment suitability for any particular investor.
📉 BMY trades at 9.4x P/E, offering 15-20% upside toward a 10x-11x multiple.
💊 Robust CAR-T pipelines and new drugs provide strong growth catalysts by 2026.
💹 Attractive 4.3% dividend yield adds value to this undervalued investment target.
📉 Bristol-Myers Squibb (BMY) stock currently trades at a low 9.4x forward P/E ratio, driven primarily by market concerns over an upcoming patent cliff.
💊 The company is considered well-equipped with a robust pipeline and significant CAR-T therapy optionality to navigate potential challenges.
📈 Investors could see 15-20% base case upside if the stock re-rates toward a 10x-11x forward P/E multiple based on new catalysts.
💹 BMY offers an attractive 4.3% dividend yield, adding to its potential as an undervalued investment target.
🚀 Key 2026 drug catalysts include Milvexian, Iberdomide, Cobenfy, and Sotyktu, which are expected to drive growth in specific indications.
🔬 The company's advanced CAR-T program features zola-cel targeting autoimmune diseases, representing a long-term growth avenue not yet fully priced into the valuation.
📝 The article author, Joseph "Kade" Minton, is an engineering physics background investor who focuses on speculative growth stocks in biotech and tech sectors.
🤖 The author posits that the biotech sector is entering a golden era with breakthroughs in cancer, Alzheimer's, and autoimmune disorder treatments.
⚠️ The analysis highlights that while patent expiration fears are prevalent, the market has significantly underpriced BMY's potential value.
🔍 The article serves as an investment thesis suggesting BMY is undervalued despite traditional risks associated with biotech patents expiring.
Bullish Signals
Bristol-Myers Squibb (BMY) trades at a discounted 9.4x forward P/E, presenting a compelling entry point with an estimated 15-20% base case upside.
The company offers a generous 4.3% dividend yield, providing downside protection and income potential for investors.
A strong pipeline of catalysts including Milvexian, Iberdomide, Cobenfy, and Sotyktu is positioned to drive a potential valuation rerating to 10x-11x forward P/E.
The advanced CAR-T program, specifically zola-cel for autoimmune diseases, provides long-term optionality that remains largely unpriced into the current stock valuation.
Despite fears of a patent cliff, management is well-equipped with a robust pipeline and significant strategic assets to sustain future growth.
Risk Factors
Bristol-Myers Squibb faces a 'major patent cliff', with multiple patents expiring within a short timeframe, which is the primary reason the stock trades at a discounted 9.4x forward P/E.
The current valuation of 9.4x forward P/E reflects significant market fears regarding revenue decline due to patent expirations.
Bristol-Myers Squibb (BMY) shares are trading at $58.30, reflecting a decline of $2.29 or 3.78% as of May 1, 2026. The company is currently on pace for its largest percentage decrease since November 14, 2025, when the stock fell 4.07%. This latest drop marks the fourth consecutive day of losses for the stock and contributes to a week characterized by poor performance, with shares down 0.70%. Notably, this weekly decline represents the worst performance since the week ending April 24, 2026, when BMY fell 2.43%.
In terms of longer-term trends, Bristol-Myers Squibb's current price is down 28.14% from its all-time closing high of $81.13 on December 2, 2022. Despite the recent decline, the stock remains up 15.29% from its closing price one year ago, which was $50.57 on May 2, 2025. The shares are also down 6.53% from its 52-week closing high of $62.37 set on February 27, 2026, but remain up 36.85% from its 52-week low of $42.60 reached on October 29, 2025. The intraday trading saw shares drop an additional 4.23% at their lowest point today, marking the largest single-day intraday decrease since April 2, 2026. Consequently, BMY ranks as the fifth worst performer within the S&P 500 for the day.
📉 BMY shares fell 3.78% in their worst weekly session since April 2026.
⏳ Stock is down roughly 28% from its 2022 all-time high.
⚠️ It ranks as the fifth-worst performer in the S&P 500 today.
📉 Bristol-Myers Squibb (BMY) shares fell 3.78% to $58.30, marking the largest percentage decrease since November 2025.
⏳ The stock is currently down for four of the past six trading sessions.
📅 This week represents BMY's worst weekly performance since late April 2026 when it fell 2.43%.
📉 Shares are down approximately 28% from their all-time closing high reached in December 2022.
⬆️ Despite recent weakness, the stock remains up over 15% compared to its price a year ago.
⬇️ The current price sits below its 52-week high of $62.37 and above its 52-week low of $42.60.
⚠️ Intraday drops hit 4.23%, the largest percentage decline observed since April 2026.
🏆 BMY was among the worst performers in the S&P 500 today, ranking fifth on the list.
📰 The data report originates from Dow Jones and is timestamped May 1, 2026.
⚠️ Morningstar includes a standard disclaimer that third-party content is not verified or endorsed.
❗ Investors are advised to seek independent financial advice before making decisions based on this market data.
🎯 The report concludes coverage of the markets and weekly wrap-up topics including energy stocks and IPO questions.
Bullish Signals
The stock remains up 15.29% from 52 weeks ago (May 2, 2025), when it closed at $50.57, demonstrating long-term value.
Bristol-Myers Squibb is up 36.85% from its 52-week closing low of $42.60 on Oct. 29, 2025, indicating significant recovery potential.
Risk Factors
Bristol-Myers Squibb (BMY) is currently at $58.30, marking a 28.14% decline from its all-time high of $81.13 reached on Dec. 2, 2022.
The stock is down 6.53% from its 52-week closing high of $62.37 recorded on Feb. 27, 2026, indicating sustained pressure below recent peaks.
BMY has been down four of the past six trading days, with the current intraday drop of 4.23% being the largest since April 2, 2026.
The stock ranks as the fifth worst performer in the S&P 500 for the current session, highlighting significant relative weakness compared to peers.
This price decline follows the company's status as being on pace for its largest percent decrease since November 14, 2025.
Bristol Myers Squibb reported solid first-quarter results with total revenue of approximately $11.5 billion, representing a 1% year-over-year increase, while its growth portfolio expanded by 9% to reach $6.2 billion. Key performers included Breyanzi, which grew 53%, and Camzyos, whose revenue nearly doubled to $314 million driven by global demand. However, Opdivo revenue decreased 8% to about $2.1 billion due to a U.S. wholesaler inventory drawdown, while Eliquis revenue rose 13% to $4.1 billion despite a U.S. price reduction that impacted collections. Other notable growth came from Reblozyl (up 15%), Sotyktu (up 20% globally), and Cobenfy ($56 million in revenue).
Gross margin declined by 280 basis points to 70.3% primarily due to product mix, while diluted EPS stood at $1.58, which included a net $0.03 per-share charge related to in-process R&D. The company ended March with approximately $11 billion in cash and marketable securities, generating roughly $1.1 billion in operating cash flow, though this was affected by about $1.2 billion in lower net cash collections from Eliquis price reductions. Chief Executive Officer Chris Boerner emphasized improved execution, stating the company is delivering a solid Q1 and maintaining shareholder-friendly capital allocation, while CFO David Elkins noted that results are trending toward the upper end of full-year 2026 guidance.
The pipeline remains a strategic focus with multiple pivotal readouts expected in late 2026 for milvexian, Cobenfy, admilparant, and iberdomide. The FDA accepted iberdomide for relapsed/refractory multiple myeloma with breakthrough therapy designation and priority review, setting a PDUFA date of August 17. Additionally, the company reported positive interim data for mezigdomide from the SUCCESSOR-2 study, showing meaningful improvement in progression-free survival, and shared positive top-line results for the antibody-drug conjugate iza-bren in a China study treating triple-negative breast cancer. The company is also pursuing $2 billion in productivity savings by end-2027 while remaining selective on business development initiatives.
📈 Q1 revenue rose 1% to $11.5B, with growth portfolio up 9% driven by new products.
💊 Key drugs Breyanzi and Camzyos surged, though Opdivo dropped due to inventory drawdowns.
💰 Company holds $11B cash, reaffirmed 2026 guidance, and pursues $2B in productivity savings.
📈 Bristol Myers Squibb reported first-quarter total revenue of approximately $11.5 billion, representing a 1% year-over-year increase.
🚀 Growth portfolio revenue reached $6.2 billion, up 9% as new products drove expansion in the business.
💊 Breyanzi sales surged 53%, while Camzyos revenue nearly doubled to $314 million amid strong global demand.
⬇️ Opdivo revenue declined 8% to $2.1 billion due to a temporary U.S. wholesaler inventory drawdown.
💉 Eliquis revenue rose 13% to $4.1 billion despite a price reduction and expected inventory normalization in Q2.
🔬 The FDA accepted the iberdomide application for multiple myeloma with priority review, targeting an August 17 decision.
🧬 Positive interim data were reported for mezigdomide showing meaningful improvement in progression-free survival.
⚖️ Gross margin declined by 280 basis points to 70.3% primarily due to product mix and lower collections from price reductions.
💰 The company ended the quarter with $11 billion in cash and equivalents while generating $1.1 billion in operating cash flow.
📉 Diluted EPS came in at $1.58, which included a net charge related to in-process R&D and licensing income.
🎯 Management reaffirmed full-year 2026 guidance and noted results are trending toward the upper end of established ranges.
💸 The company is pursuing approximately $2 billion in productivity savings by the end of 2027 through strategic initiatives.
📊 Opdualag continued to post double-digit growth, while Sotyktu increased 20% globally following a new approval.
🔗 Additional revenue came from Qvantig ($163M), Cobenfy ($56M), and Reblozyl (which grew 15%).
👨💼 CEO Chris Boerner emphasized disciplined execution and improving the company's "say-do ratio" across operations.
🗓️ Late 2026 is identified as a key period for multiple pivotal readouts including milvexian and new ADC data.
Bullish Signals
Bristol Myers Squibb delivered solid Q1 results with total revenue of approximately $11.5 billion, marking a 1% year-over-year increase.
The growth portfolio increased by 9% to $6.2 billion, demonstrating strong momentum in high-potential product lines.
Breyanzi revenue grew 53%, attributed to its best-in-class profile and demand across approved indications in the U.S. and international markets.
Camzyos revenue nearly doubled to $314 million, driven by continued global demand for the heart condition treatment.
Eliquis revenue increased 13% to approximately $4.1 billion, reflecting strong underlying demand despite recent price reductions.
Reblozyl grew 15%, showing continued uptake in first- and second-line treatments for MDS-associated anemia.
Sotyktu achieved a 20% global growth rate following its recent approval in psoriatic arthritis, with positive potential in lupus and Sjögren's disease pipelines.
Opdualag posted another quarter of double-digit growth, reinforced by global demand and its status as the standard of care in first-line melanoma treatment.
The company secured major regulatory milestones, including FDA acceptance of iberdomide for multiple myeloma with breakthrough therapy designation and a PDUFA date of Aug. 17.
Management highlighted positive phase III interim data for mezigdomide, which demonstrated meaningful improvement in progression-free survival.
Bristol Myers Squibb reaffirmed its full-year 2026 guidance, tracking toward the upper end of established ranges, signaling management confidence.
The company ended March with a robust $11 billion in cash equivalents and marketable securities while maintaining disciplined capital allocation.
Risk Factors
Opdivo revenue declined 8% to $2.1 billion, driven by a U.S. wholesaler inventory drawdown with levels at the low end of the typical range.
Eliquis collections were negatively impacted by a U.S. price reduction implemented at the start of the year and increased generic entry across several other brands.
Gross margins contracted 280 basis points to 70.3%, primarily due to product mix shifts rather than operational efficiency gains.
Operating expenses rose slightly above the prior-year period at $3.9 billion, partly due to incremental investments in new drug candidates.
The company recorded a net $0.03 per-share charge related to in-process R&D and licensing income which impacted diluted EPS of $1.58.
Cash collections were down approximately $1.2 billion quarter-over-quarter tied to the Eliquis list price reductions, creating near-term headwinds for cash flow.
Management reaffirmed full-year 2026 guidance while pursuing productivity savings, indicating ongoing pressure to manage costs and margins amidst growth investments.
Bristol Myers Squibb (BMY) reported first-quarter earnings that exceeded Wall Street expectations, driven by strong growth in key pharmaceuticals like Eliquis and newer cancer therapies. The company posted adjusted earnings of $1.58 per share, surpassing the analyst consensus of $1.42, while revenue reached $11.49 billion against a forecast of approximately $10.9 billion. Shares rose 4% following the announcement. Eliquis, sold in partnership with Pfizer, contributed $4.14 billion to quarterly sales, reflecting a 16% year-over-year increase and maintaining over 75% of the new prescription share, indicating sustained demand. Growth from newer medicines, including cell therapies like Breyanzi and Camzyos, helped offset declines in older products such as Revlimid, which has faced generic competition. The revenue from this growth portfolio increased 12% to $6.23 billion, representing more than half of total revenue.
Despite the overall beat, some analysts noted mixed performance in specific areas. RBC Capital Markets analyst Trung Huynh pointed out that while the quarterly result was positive, the long-term outlook relies more on catalysts expected in the second half of 2026, such as approvals for next-generation cancer drugs and late-stage study results for milvexian and Cobenfy. Additionally, Opdivo sales dropped 5% to $2.15 billion, missing estimates of $2.33 billion, which finance chief David Elkins attributed to wholesalers reducing inventory levels, a situation the company is monitoring closely. The company also recorded $163 million in sales for its recently launched subcutaneous version, Opdivo Qvantig.
Looking forward, Bristol Myers Squibb reaffirmed its full-year 2026 outlook with projected revenue between $46.0 billion and $47.5 billion and adjusted earnings per share ranging from $6.05 to $6.35, expecting results to trend toward the higher end of these ranges. CEO Chris Boerner highlighted strategic initiatives, including expanding artificial intelligence usage in research and development to identify potential drug molecules 50% faster and reduce clinical development cycle times by 30%. Ongoing cost-cutting efforts have already yielded $1 billion from a planned $2 billion savings target by the end of 2025, with the full amount expected by the end of next year. These savings are intended to support investment in new medicines and dividend growth.
📈 Q1 adjusted earnings of $1.58 beat estimates, driving shares up 4%.
💰 Revenue hit $11.49 billion with Eliquis sales rising 16%.
🚀 Growth portfolio and AI adoption continue to drive innovation and efficiency.
📈 Bristol Myers Squibb reported Q1 adjusted earnings of $1.58 per share, beating the analyst average expectation of $1.42.
💰 Revenue came in at $11.49 billion, surpassing expectations of approximately $10.9 billion and driving shares up 4%.
💉 Sales of Eliquis reached $4.14 billion, a 16% increase year-over-year with new prescription share exceeding 75%.
🚀 Growth portfolio sales rose 12% to $6.23 billion, accounting for more than half of the company's total revenue.
🛡️ Newer cancer medicines like Breyanzi and Camzyos helped offset steep declines in older products facing generic competition.
⚠️ Analysts noted that Opdivo sales fell 5% to $2.15 billion, missing estimates due to wholesalers reducing inventory levels.
🔬 The company added another $163 million in revenue from Opdivo Qvantig, the subcutaneously injected version launched last year.
💡 Bristol Myers reaffirmed its 2026 outlook for revenue between $46.0 billion and $47.5 billion with earnings trending toward the higher end.
🤖 The CEO announced AI use in R&D will speed up drug molecule identification by 50% and cut clinical development times by 30%.
💸 Ongoing cost-cutting efforts have delivered $1 billion of planned savings, with a target to hit the full $2 billion by year-end.
📉 Analyst Trung Huynh highlighted mixed performance in growth drivers like Opdivo and Reblozyl as key considerations for future quarters.
📅 Analysts believe 2026 catalysts such as next-generation cancer drug approvals and late-stage study results will be critical.
Bullish Signals
Adjusted earnings hit $1.58/share, beating estimates.
Bristol Myers Squibb reported first-quarter adjusted earnings of $1.58 per share, significantly beating analyst expectations of $1.42.
Revenue reached $11.49 billion, surpassing the estimated target of approximately $10.9 billion.
Shares rose 4% following the strong quarterly performance driven by better-than-expected growth in key medicines.
Eliquis sales grew 16% year-over-year to $4.14 billion, with new prescription share now surpassing 75% of the market.
Growth from newer cancer medicines and the expansion of Opdivo Qvantig helped offset declines in older products facing generic competition.
Sales from the growth portfolio increased 12% to $6.23 billion, accounting for more than half of total revenue.
The company reaffirmed its 2026 revenue guidance of $46.0 billion to $47.5 billion with results trending toward the higher end.
CEO Chris Boerner highlighted that AI usage will accelerate drug molecule identification by about 50% and reduce clinical development cycle times by 30%.
Cost-cutting efforts have delivered $1 billion in savings, with the full $2 billion target on track to be met by the end of 2026.
Ongoing investment in newer medicines and dividend growth is supported by current cost-saving initiatives.
Risk Factors
Revenue growth from older products is being offset by steep declines in key legacy medicines due to generic competition, such as Revlimid.
Sales of the original formulation of Opdivo dropped 5% to $2.15 billion, missing analyst estimates of $2.33 billion due to wholesalers reducing inventory levels.
Finance chief David Elkins expressed uncertainty about whether inventory levels will normalize over the balance of the year regarding Opdivo sales.
Analyst Trung Huynh warned that the beat was outweighed by mixed performance in some growth drivers, specifically noting declines for cancer drug Opdivo and anemia treatment Reblozyl.
The company's reliance on newer medicines has increased, with the growth portfolio accounting for more than half of total revenue at $6.23 billion.
Future stock performance may depend less on 2026 quarters and more on late-stage study results from milvexian and Cobenfy in H2 2026, introducing execution risk.
Bristol-Myers Squibb (NYSE: BMY) has garnered renewed attention following the release of positive Phase 3 data for its drug Camzyos in adolescents with obstructive hypertrophic cardiomyopathy and the announcement of a multi-year collaboration focused on T-cell engager therapeutics with Oxford BioTherapeutics. The company is currently trading at a share price of US$59.47, which corresponds to a nine-day return of 6.46% and an 11.24% year-to-date gain, while the one-year total shareholder return stands at 23.74%. Analysts and the platform analyzing the stock suggest that these positive developments in late-stage pipeline news are driving momentum for the healthcare giant.
Financially, Bristol-Myers Squibb reported full-year 2024 revenues of $48.3 billion, representing a 7% increase from 2023 figures. Despite a GAAP loss per share of $(4.41) compared to $3.86 in 2023, the company demonstrated resilience with non-GAAP earnings per share of $1.15 and significant growth in its newer product portfolio, which generated $22.6 billion in revenue, a 17% increase from the previous year. The analysis indicates that the current market price of US$59.47 trades at a discount to both the US$63.04 average analyst target and a calculated fair value narrative of US$65.00, leading analysts to classify the stock as undervalued with a value score of 5.
The positive valuation outlook relies heavily on the sustained momentum of its growing portfolio of newer products alongside optimistic margin assumptions. However, there are significant risks that could challenge this bullish narrative, specifically if growth portfolio momentum slows down or if projected cost savings and earnings guidance fail to translate into more stable reported profitability. The article notes that investor opinions remain split between concerns over these potential headwinds and optimism regarding the upcoming rewards from recent data releases and partnerships, resulting in a fair value assessment that suggests the gap between the current price and the US$65.00 fair value is hard to ignore.
📈 BMY shares gained 11% YTD with 23.74% total annualized return so far.
💰 Stock trades at a 9% discount to estimated fair value of US$65.00.
📊 Full-year revenue grew 7% to $48.3B, led by growth portfolio surge.
⚠️ GAAP loss widened due to restructuring costs despite strong new product sales.
💡 Investment focuses on future margins from newer therapies rather than legacy earnings.
📈 Bristol-Myers Squibb (BMY) shares closed at US$59.47, reflecting positive momentum following recent data releases and partnerships.
💖 The company released positive Phase 3 data for its drug Camzyos in adolescents with obstructive hypertrophic cardiomyopathy.
🤝 BMY announced a new multi-year collaboration to develop T-cell engager therapeutics with Oxford BioTherapeutics.
📊 Year-to-date share price return stands at 11.24%, contributing to an annualized total shareholder return of 23.74%.
💰 At the current share price, BMY trades at a discount to its average analyst target price of US$63.04.
📉 Full-year 2024 revenues reached $48.3 billion, representing a 7% increase compared to 2023.
❌ GAAP loss per share widened to $(4.41) in 2024 from earnings of $3.86 in 2023 due to investment and restructuring costs.
📈 Non-GAAP EPS decreased significantly to $1.15, down from $7.51 in the previous year.
🌱 Growth portfolio revenues jumped 17% year-over-year to $22.6 billion, indicating strong performance of newer products.
💡 Simply Wall St calculates a fair value of US$65.00 for BMY, suggesting the stock is currently undervalued by roughly 9%.
⚠️ Investors face risks if growth portfolio momentum slows or if cost savings fail to stabilize reported profitability.
🛡️ Simply Wall St highlights that the company holds a "fair value" narrative despite current GAAP losses driven by strategic investments.
🔄 The investment thesis relies on newer products driving future margins and valuation rather than legacy oncology earnings alone.
Bullish Signals
Phase 3 Camzyos data in adolescents strengthens pipeline.
New T-cell engager collaboration adds oncology potential.
Growth portfolio revenues reached $22.6 billion, up 17% from 2023.
Total shareholder return of 23.74% reflects strong momentum.
Stock trades at discount to $65 fair value target.
Full-year 2024 revenues reached $48.3 billion, up 7% from 2023.
Non-GAAP EPS for 2024 was $1.15 showing profitability.
Analysts suggest stock undervalued at current price of $59.47.
Focus on newer products supports long-term revenue growth.
GAAP loss widened to $(4.41) from 2023 $3.86 earnings.
Non-GAAP EPS fell from $7.51 in 2023 to $1.15.
Stock trades at US$59.47 versus US$65.00 fair value target.
Valuation depends on future growth which could easily reverse.
Profitability risks if cost savings fail to translate efficiently.
Bullish Signals
Bristol-Myers Squibb announced positive Phase 3 data for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy, strengthening its pipeline.
A new multi-year T-cell engager collaboration with Oxford BioTherapeutics adds significant oncology potential to the company's portfolio.
Growth Portfolio Revenues reached $22.6 billion, representing a robust 17% increase from 2023, highlighting strong performance of newer products.
Total shareholder return over the past year was 23.74%, demonstrating building momentum around recent Camzyos data and oncology collaborations.
The stock currently trades at a modest discount to analyst targets with a fair value assessment of $65.00 versus the current price of $59.47, suggesting potential upside.
Full-Year 2024 Total Revenues were $48.3 billion, marking a 7% increase from 2023.
Non-GAAP EPS for 2024 was $1.15, indicating profitability metrics despite GAAP loss.
Analyst consensus suggests the stock is undervalued with a calculated fair value of $65.00.
The company's focus on a growing set of newer products supports long-term revenue growth.
Recent positive catalysts including Camzyos data and new collaborations have strengthened investor sentiment.
Risk Factors
GAAP loss per share widened significantly to $(4.41) from earnings of $3.86 in 2023, indicating deteriorating core profitability despite overall revenue growth.
Non-GAAP EPS dropped substantially from $7.51 in 2023 to just $1.15, suggesting a potential mismatch between current valuation assumptions and recent earnings performance.
The company is trading at a share price of US$59.47 against a fair value target of US$65.00, but the gap relies on future growth momentum that could easily reverse if newer product sales slow down.
Analyst consensus targets the stock at US$63.04, meaning current investor sentiment may already be pricing in some positive developments from recent clinical trial data and collaborations.
The valuation narrative depends heavily on cost savings successfully translating into stable reported profitability, creating a key risk if management fails to deliver on efficiency gains.
Bristol-Myers Squibb shares gained 10.2% year to date, significantly outperforming the biotechnology industry's 1.6% growth and the broader S&P 500 index as of late April. This sustained rally has helped restore investor confidence in the company's ability to navigate generic competition eroding revenues from legacy products. The positive momentum is driven by a robust growth portfolio, which accounted for approximately 55% of total revenues in 2025, anchored by key drugs such as Opdivo, Orencia, Reblozyl, Camzyos, Breyanzi, and the newer schizophrenia treatment Cobenfy.
The legacy portfolio continues to face structural headwinds from generic competition, resulting in a 15% revenue decline in 2025, with key affected products including Revlimid, Pomalyst, Sprycel, and Abraxane. This segment generated 45% of total 2025 revenues, totaling $48.2 billion, though demand for Eliquis remains solid. Management expects a 12-16% decline in the legacy portfolio in 2026 due to ongoing patent expiries and pricing headwinds, while Eliquis is forecast to grow 10-15%. Additional policy-driven pressure will include supplying Eliquis at no cost to Medicaid under a new agreement effective January 1, 2026, along with significant discounts on other products like Sotyktu and Orencia SC for eligible cash-paying patients.
Bristol-Myers Squibb's growth trajectory is further supported by a deep pipeline and recent strategic acquisitions. The company expects top-line registrational data in 2026 for six candidates, including milvexian and admilparant. Recent positive interim results from the late-stage SUCCESSOR-2 study for mezigdomide marked an important milestone for its next-generation CELMoD program, reinforcing confidence in its targeted protein degradation platform. Additionally, the recent acquisition of Orbital Therapeutics added OTX-201, a preclinical RNA CAR-T therapy, and in 2025, the company partnered with BioNTech to co-develop pumitamig for solid tumors, highlighting ongoing efforts to expand its therapeutic options despite market challenges.
💰 Eliquis generated $48.2B in 2025 revenue despite generic pressures.
⚡ Growth Portfolio contributed 55% of total revenues driven by oncology drugs.
🧬 Pipeline includes six candidates expected to report data in 2026.
🤝 Legacy portfolio guides 12-16% revenue decline for 2026 due to expiries.
📈 BMY shares have gained 10.2% year-to-date, significantly outperforming the industry's 1.6% growth and the S&P 500.
💊 The Growth Portfolio comprised about 55% of total revenues in 2025, driven largely by the immuno-oncology franchise.
⚡ Opdivo remains the top revenue contributor, supported by label expansions and share gains in non-small cell lung cancer.
🔬 Opdualag has become a standard-of-care option for first-line melanoma in the United States with robust growth.
💰 Reblozyl partnered with Merck & Co has surpassed $2 billion in annualized sales due to strong adoption in anemia treatments.
🧪 Breyanzi crossed a $1 billion run rate in large B-cell lymphoma, with further growth anticipated for 2026.
⚖️ Cobenfy generated $155 million in 2025 sales as the first novel pharmacological approach to schizophrenia in decades.
📉 The legacy portfolio faced a 15% revenue decline in 2025 due to generic competition affecting products like Revlimid and Pomalyst.
💵 Eliquis, co-developed with Pfizer, generated 45% of total 2025 revenues ($48.2 billion) despite generic pressures.
📅 Management guides for a 12-16% decline in the legacy portfolio for 2026 due to patent expiries and pricing headwinds.
🛑 Eliquis will be supplied at no cost to Medicaid starting Jan. 1, 2026, under a new U.S. agreement affecting net pricing.
🧬 BMY's pipeline includes six candidates expected to report top-line registrational data in 2026 for various indications.
✨ The company recently reported positive interim results from the late-stage SUCCESSOR-2 study for mezigdomide in multiple myeloma.
🤝 The acquisition of Orbital Therapeutics adds OTX-201, a preclinical RNA CAR-T therapy, to expand the autoimmune disease portfolio.
Bullish Signals
Shares gained 10.2% YTD vs 1.6% industry growth.
Growth Portfolio represents 55% of 2025 revenues.
Opdivo remains leading revenue contributor.
Opdualag delivering robust US growth in melanoma.
Reblozyl surpassed $2B in annualized sales.
Breyanzi crossed $1B run rate.
Cobenfy generated $155M in 2025 sales.
Six candidates expected to report 2026 data.
SUCCESSOR-2 study shows positive interim results.
Risk Factors
Legacy portfolio faces 15% revenue decline in 2025 from generic competition.
Management projects 12-16% additional revenue decline for legacy segment in 2026.
Eliquis supply at no cost to Medicaid effective Jan. 1, 2026 pressures margins.
Growth products face discounts to cash patients impacting revenue.
Eliquis growth only partially offsets legacy segment declines.
Shares up 10.2% vs 1.6% industry growth signals overvaluation risk.
Generic erosion creates persistent structural headwinds for core revenues.
Bullish Signals
Bristol Myers Squibb shares have gained 10.2% year to date, significantly outperforming the industry's growth of 1.6% and both the sector and S&P 500.
The company's Growth Portfolio accounts for approximately 55% of total revenues in 2025, anchored by key drugs like Opdivo, which remains the leading revenue contributor due to continued label expansions and sustained share gains in first-line non-small cell lung cancer.
Opdualag continues to deliver robust growth in the United States, becoming a standard-of-care option in first-line melanoma.
Reblozyl has surpassed $2 billion in annualized sales with strong adoption across both first- and second-line MDS-associated anemia.
Breyanzi has crossed a $1 billion run rate, reflecting solid uptake in large B-cell lymphoma with further growth anticipated in 2026.
Cobenfy generated $155 million in 2025 sales as access expands and adoption deepens, representing a potentially meaningful long-term growth driver for schizophrenia.
BMY expects to report top-line registrational data for six candidates in 2026 across various indications including atrial fibrillation, idiopathic pulmonary fibrosis, and multiple myeloma.
The company recently announced positive interim results from the late-stage SUCCESSOR-2 study for mezigdomide, marking an important milestone for its next-generation CELMoD program.
Risk Factors
The legacy portfolio faces a projected 15% revenue decline in 2025 due to generic competition affecting key products like Revlimid, Pomalyst, Sprycel, and Abraxane.
Management guides for an additional 12-16% revenue decline in the legacy portfolio for 2026, driven by ongoing patent expiries and pricing headwinds.
Policy-driven changes introduce incremental pressure on net pricing and margins, with Eliquis to be supplied at no cost to Medicaid under a new U.S. agreement effective Jan. 1, 2026.
Several growth products, including Sotyktu, Zeposia, and Orencia SC, will face significant discounts to eligible cash-paying patients, potentially impacting revenue growth from these assets.
While Eliquis is expected to deliver 10-15% growth, this is noted as only partially mitigating the overall legacy segment decline in coming years.
The article acknowledges that Bristol Myers' shares have gained 10.2% year-to-date compared to the industry's 1.6% growth, which may signal overvaluation relative to broader sector performance.
Generic erosion of legacy products remains a structural headwind that requires continued navigation, suggesting persistent challenges in core revenue streams.
Your Privacy
We use cookies to:
Deliver and maintain our services, protect against spam, fraud and abuse
Measure audience engagement and site statistics to understand how our services are used (Google Analytics)
Remember your quiz progress and tailor the knowledge base to your skill level (optional)
You can accept all cookies or configure your preferences. You can change them at any time via the "Manage Cookies" link in the footer.
Manage cookie preferences
Necessary cookiesAlways active
Required for the website to function. These cannot be disabled.
Cookie
Purpose
Duration
PHPSESSID
Session identifier for login, security tokens, and site functionality
Session
cookie_consent
Stores your cookie preferences
1 year
Analytics cookies
Help us understand how visitors interact with our website using Google Analytics. These cookies collect information anonymously.
Cookie
Purpose
Duration
_ga
Distinguishes unique visitors (Google Analytics)
2 years
_ga_*
Maintains session state (Google Analytics)
2 years
Personalization cookies
Remember your quiz progress and work out your investing level so we can recommend knowledge-base articles and the right reading depth for you. Stored only on your device.
Cookie
Purpose
Duration
bes_user_level
Your quiz-derived investing level, used to tailor content
